Anticorps Polyclonal de lapin anti-c-MYC

• Phare
• Validé par KD/KO

c-MYC Polyclonal Antibody for WB, IF/ICC, FC (Intra), IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain et plus (4)

Applications

WB, IF/ICC, FC (Intra), IP, CoIP, ChIP, ELISA, EMSA

Conjugaison

Non conjugué

Publications

617

Avis (4)

N° de cat : 10828-1-AP

Synonymes

MYC, Myc proto oncogene protein, MRTL, Class E basic helix-loop-helix protein 39, c Myc

---

Galerie de données de validation

• 

  WB analysis of A549 using 10828-1-AP

  WB result of c-MYC antibody (10828-1-AP; 1:12000; incubated at room temperature for 1.5 hours) with sh-Control and sh-c-MYC transfected A549 cells.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 10828-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HL-60 using 10828-1-AP

  HL-60 cells were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human placenta using 10828-1-AP

  human placenta tissue were subjected to SDS PAGE followed by western blot with 10828-1-AP (c-MYC antibody at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IP experiment of MCF-7 using 10828-1-AP

  IP result of anti-c-MYC (IP:10828-1-AP, 4ug; Detection:10828-1-AP 1:1000) with MCF-7 cells lysate 1660 ug.

• 

  IF Staining of U2OS using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed U2OS cells using c-MYC antibody (10828-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red).

• 

  IF Staining of HEK-293 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HEK-293 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red).

• 

  IF Staining of Saos-2 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed Saos-2 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

• 

  IF Staining of Saos-2 using 10828-1-AP

  Immunofluorescent analysis of (4% PFA) fixed Saos-2 cells using c-MYC antibody (10828-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

• 

  FC experiment of HeLa using 10828-1-AP

  1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human c-MYC (10828-1-AP) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).

---

Applications testées

• Résultats positifs en WB: cellules HT-29, cellules A549, cellules BxPC-3, cellules HeLa, cellules HepG2, cellules HL-60, cellules Jurkat, cellules Jurkat et cellules Raji, cellules Raji, cellules SH-SY5Y, cellules SW-1990, tissu placentaire humain
• Résultats positifs en IP: cellules MCF-7,
• Résultats positifs en IF/ICC: Saos-2 cells, cellules HEK-293, cellules U2OS
• Résultats positifs en FC (Intra): cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:12000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 25 publications below
• WB: See 560 publications below
• IF: See 36 publications below
• IP: See 21 publications below
• CoIP: See 15 publications below
• ChIP: See 12 publications below

Informations sur le produit

10828-1-AP cible c-MYC dans les applications de WB, IF/ICC, FC (Intra), IP, CoIP, ChIP, ELISA, EMSA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: rat, Humain, porc, poulet, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: c-MYC Protéine recombinante Ag1263
• Nom complet: v-myc myelocytomatosis viral oncogene homolog (avian)
• Masse moléculaire calculée: 49 kDa
• Poids moléculaire observé: 62-65 kDa, 50 kDa
• Numéro d’acquisition GenBank: BC000141
• Symbole du gène: MYC
• Identification du gène (NCBI): 4609
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Function

c-Myc (also known as Myc), together with l-Myc and n-Myc, belongs to the Myc family of transcription factors. c-Myc has a basic helix-loop-helix leucine zipper domain and through heterodimerization can bind and regulate the transcriptional activity of genes, either by repression or activation. It is a key player in the regulation of cell growth and cell cycle progression and acts as a proto-oncogene.

Tissue specificity

c-Myc is ubiquitously expressed in almost all cell types and its expression positively correlates with tissue proliferative capacity. c-Myc is also expressed during embryogenesis and is upregulated in many cancer types.

Involvement in disease

·         Upregulated in many cancer types, especially in aggressive, poorly differentiated tumors.

·         Mutations in the MYC gene and breakpoint translocations within the MYC gene cause Burkitt lymphoma.

Isoforms

There are 3 different isoforms of c-Myc: c-Myc1, c-Myc2, and c-MycS (PMID: 16260605). They differ in molecular size, can be preferentially expressed during cell growth, and are reported to be functionally distinct. The 50kDa band recognized by antibody is the native form of MYC, while the other bands, between 60-70kDa, are the phosphorylated form of MYC (PMID: 12189186).

Post-translational modifications

c-Myc is subject to various post-translational modifications, including phosphorylation, acetylation, and ubiquitinylation (PMID: 16987807), which regulate its activity.

Cellular localization

c-Myc localizes to the nucleus but can also be present in the cytoplasm of certain cancer types.

Publications

Species	Application	Title
human	WB	Nature; RIC-seq for global in situ profiling of RNA-RNA spatial interactions.; Authors - Zhaokui Cai
mouse	WB	Signal Transduct Target Ther; MDIG-mediated H3K9me3 demethylation upregulates Myc by activating OTX2 and facilitates liver regeneration; Authors - Jinpeng Du ; KD Validated
human	WB	Signal Transduct Target Ther; Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.; Authors - Xuewen Liu
human	WB,IF	Gastroenterology; Nucleolar HEATR1 upregulated by mTORC1 signaling promotes hepatocellular carcinoma growth by dominating ribosome biogenesis and proteome homeostasis; Authors - Xiao-Mei Yang
human	WB	Cancer Cell; p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.; Authors - Alessandro Carugo ; KD Validated
	WB	Cell Metab; Efferocytosis induces macrophage proliferation to help resolve tissue injury.; Authors - Brennan D Gerlach ; KD Validated

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Molly (Verified Customer) (05-02-2023)

The antibody worked well for western blotting following the recommended protocol.

• Applications: Western Blot
• Primary Antibody Dilution: 1:2000
• Cell Tissue Type: Ewing sarcoma cell lines

FH

Anna-Maria (Verified Customer) (08-13-2019)

This antibody worked as expected for western blotting

• Applications: Western Blot,
• Primary Antibody Dilution: 1:1000
• Cell Tissue Type: Bladder cancer cell lines

FH

Christine (Verified Customer) (11-13-2018)

The antibody worked better than the Abcam c-Myc antibody. However, I did not get clear nuclear staining but rather a mix of nuclear staining with cytoplasmic staining. This could be due non-optimized conditions.

• Applications: Immunohistochemistry,
• Primary Antibody Dilution: 1 to 300
• Cell Tissue Type: Colon

FH

Claudio (Verified Customer) (12-14-2017)

We tested the antibody in IHC/IFL on mouse brain tumors that showed c-myc upregulation at the mRNA level.

• Applications: Immunohistochemistry, Immunofluorescence
• Primary Antibody Dilution: 100
• Cell Tissue Type: Mouse brain tumors with c-myc upregulation (determined at the mRNA level)

Produits associés

P53 Polyclonal antibody

10442-1-AP

MAX Polyclonal antibody

10426-1-AP

human BCL2 Polyclonal antibody

12789-1-AP

Cyclin D1 Monoclonal antibody

60186-1-Ig

Beta Catenin Polyclonal antibody

51067-2-AP

MYCN Polyclonal antibody

10159-2-AP

P21 Monoclonal antibody

60214-1-Ig